Literature DB >> 6361599

Factors in predicting outcome from operation in patients with prolactin-secreting pituitary adenomas.

P B Nelson, M Goodman, J C Maroon, A J Martinez, J Moossy, A G Robinson.   

Abstract

Forty female patients with pituitary adenomas were studied retrospectively to determine whether factors could be identified that would help predict outcome from operation. Twenty-five patients had a normal prolactin level (less than or equal to 30 ng/ml) during the early postoperative period (less than or equal to 3 months) and 15 patients had persistent disease (prolactin greater than 30 ng/ml). Nine of the 25 patients who initially had normal prolactin levels during the early postoperative period were found to have elevated prolactin levels during the late postoperative period (greater than 3 months). As has been shown previously, tumor size and preoperative prolactin levels were important factors in predicting surgical outcome. Patients with smaller (Hardy Grades I and II) tumors had significantly better outcome than those with larger (Hardy Grades III and IV) tumors. Patients with successful surgical outcomes had significantly lower preoperative prolactin values (204 ng/ml) than those with operative failures (524 ng/ml). In addition to the known factors, the patient's age at the time of operation, the length of amenorrhea, and the patient's growth hormone response to insulin hypoglycemia were newly identified as factors that helped predict surgical outcome. Patients who were less than or equal to 26 years of age and who had had amenorrhea for less than or equal to 6 years at the time of operation had significantly better surgical outcomes. Patients with normal growth hormone responses to stimulation testing had significantly better surgical outcomes than those with a blunted preoperative growth hormone response. The data suggest that prolactin-secreting pituitary tumors may cause a progressive disorder for which operative cure may be obtained only early in the disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6361599     DOI: 10.1227/00006123-198312000-00002

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  7 in total

1.  Enlarged adenomectomy for enclosed prolactinomas: a preliminary study of 26 cases.

Authors:  F Grisoli; T Brue; N Graziani; R Costa; J Trouillas; D Begou; P Jaquet
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

2.  Surgical treatment of prolactinomas: cons.

Authors:  Eve Bloomgarden; Mark E Molitch
Journal:  Endocrine       Date:  2014-08-12       Impact factor: 3.633

3.  Estrogen receptors in prolactinomas: a clinico-pathological study.

Authors:  G J Kaptain; N E Simmons; T D Alden; M B Lopes; M L Vance; E R Laws
Journal:  Pituitary       Date:  1999       Impact factor: 4.107

4.  Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.

Authors:  Eun-Hee Cho; Sang Ah Lee; Ji Youn Chung; Eun Hee Koh; Young Hyun Cho; Jeong Hoon Kim; Chang Jin Kim; Min-Seon Kim
Journal:  J Korean Med Sci       Date:  2009-09-24       Impact factor: 2.153

Review 5.  Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

6.  Bromocriptine therapy for the treatment of invasive prolactinoma: the single institute experience.

Authors:  Kyung Rae Cho; Kyung-Il Jo; Hyung Jin Shin
Journal:  Brain Tumor Res Treat       Date:  2013-10-31

7.  Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis.

Authors:  Xiangming Cai; Junhao Zhu; Jin Yang; Chao Tang; Zixiang Cong; Chiyuan Ma
Journal:  Chin Neurosurg J       Date:  2022-04-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.